Request an Appointment

Liver Transplant Program

Clinical trials

Below are current clinical trials.


27 studies in Liver Transplant Program
(open studies only).

Filter this list of studies by location, status and more.

  1. Non-Invasive Method of Diagnosing Rejection for Liver Transplant Patients

    Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

    The purpose of this study is to validate the use of a RNAseq-based peripheral blood assay in liver transplant recipients when correlated to liver biopsy results.

  2. Risk-Based Therapy in Treating Younger Patients with Newly Diagnosed Liver Cancer

    Rochester, Minn.

    This phase III trial studies the side effects and how well risk-based therapy works in treating younger patients with newly diagnosed liver cancer. Surgery, chemotherapy drugs (cancer fighting medicines), and when necessary liver transplant are the main current treatments for hepatoblastoma. The stage of the cancer is one factor used to decide the best treatment. Treating patients according to the risk group they are in may help get rid of the cancer, keep it from coming back, and decrease the side effects of chemotherapy.

  3. A Study of Donated Alloantigen Reactive Regulatory T Cells for Reducing or Discontinuing Immune System Suppression in Liver Transplant Patients

    Rochester, Minn.

    This research study is for liver transplant recipients and their respective living donors. The purpose of this study is to see if it is safe for liver recipients to receive one dose of donor reactive T regulatory cells (Tregs), and if the Tregs allows a liver recipient to take less, or completely stop medications normally taken after receiving an organ transplant.

  4. A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

    Scottsdale/Phoenix, Ariz., Rochester, Minn.

    A Phase 3b, single arm, open-label, multicenter study to evaluate the safety and to demonstrate the non-inferiority of the sustained virologic response 12 weeks post dosing (SVR12) rates of 8 weeks of treatment with the glecaprevir (GLE)/pibrentasvir (PIB) combination regimen to the historical SVR12 rate of 12 weeks of treatment with the GLE/PIB in treatment-naïve adults with chronic HCV GT 1, 2, 4, 5, or 6 infection and compensated cirrhosis.

  5. A Study of Predictors of Renal Insufficiency Following Orthotopic Liver Transplantation

    Rochester, Minn.

    The purpose of this study is to see if certain pre-transplant markers are able to predict how the kidney will respond after a liver transplant.

  6. Study to Assess Safety and Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid

    Scottsdale/Phoenix, Ariz.

    The purpose of this study is to assess the safety and efficacy of GKT13783 in patients with Primary Biliary Cholangitis (PBC) who are taking a stable dose of ursodeoxycholic acid (UDCA) treatment, and have persistently high levels of a liver enzyme called Alkaline Phosphatase (ALP).

  7. Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

    Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

    The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.

  8. A Study to Confirm the Effectiveness and Safety of Terlipressin for Treatment of Hepatorenal Syndrome Type 1

    Scottsdale/Phoenix, Ariz., Rochester, Minn.

    The purpose of this study is to confirm the effectiveness and safety of  terlipressin in the treatment of adult patients with hepatorenal syndrome (HRS) type 1.

  9. A Study to Better Understand Why Patients Gain Weight After Undergoing Liver Transplantation

    Rochester, Minn.

    The purpose of this study is to understanding the mechanisms of weight gain in patients following liver transplantation, action, and indicate approaches to prevent weight gain.

  10. Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

    Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

    This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite clinical endpoint (where all-cause mortality, new decompensation events, and MELD score progression are events) in subjects with decompensated NASH cirrhosis.

  1. 1
  2. 2
  3. 3
  4. Next
Request an Appointment at Mayo Clinic
Locations, travel & lodgingResearch
Jan. 17, 2018
References
  1. Scientific Registry of Transplant Recipients. http://www.srtr.org/default.aspx. April 11, 2016.
  2. U.S. News & World Report. U.S. News Best Hospitals 2015-16. http://health.usnews.com/best-hospitals/rankings. Accessed Feb. 22, 2016.
  3. Barbara Woodward Lips Patient Education Center. Liver transplant. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2013.
  4. Eggebraaten KR (expert opinion). Mayo Clinic, Rochester, Minn. May 23, 2016.
  5. Barbara DW, et al. The perioperative management of patients undergoing combined heart-liver transplantation. Transplantation. 2015;99:139.
  6. Bulatao IG, et al. Avoiding stay in the intensive care unit after liver transplantation: A score to assign location of care. American Journal of Transplantation. 2014;14:2088.
  7. Heimbach JK (expert opinion). Mayo Clinic, Rochester, Minn. June 28, 2016.
  8. Stulak JM, et al. Combined heart and abdominal organ transplantation: Excellent outcomes gained from a unique experience. Journal of Heart and Lung Transplantation. 2014;33:S278.
  9. Ibrahim SH (expert opinion). Mayo Clinic, Rochester, Minn. June 14, 2016.
  10. Glorioso JM, et al. Pivotal preclinical trial of the spheroid reservoir bioartificial liver. Journal of Hepatology. 2015;63:388.
  11. Heimbach JK, et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. American Journal of Transplantation. 2013;13:363.
  12. Murad SD, et al. Long-term clinical and radiological follow up of living liver donors. Liver Transplantation. In press. Accessed May 11, 2016.
  13. Murad SD, et al. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology. 2012;56:973.
  14. Barbara Woodward Lips Patient Education Center. About your child's liver transplant. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2009.
  15. Rizvi S, et al. Primary sclerosing cholangitis as a premalignant biliary tract disease: Surveillance and management. Clinical Gastroenterology and Hepatology. 2015;13:2152.
  16. Taner T, et al. Decreased chronic cellular and antibody-mediated injury in the kidney following simultaneous liver-kidney transplantation. Kidney International. 2016;89:909.
  17. Watt KD, et al. A practical guide to the management of HCV infection following liver transplantation. American Journal of Transplantation. 2009;9:1707.
  18. Rosen CB, et al. Liver transplantation for cholangiocarcinoma. Transplant International. 2010;23:692.
  19. Raichlin E, et al. Combined heart and liver transplantation: A single-center experience. Transplantation. 2009;88:219.
  20. Nagourney E. 'Domino' transplants: Rare and risky. The New York Times. http://www.nytimes.com/2000/05/02/health/domino-transplants-rare-and-risky.html. Accessed May 12, 2016.
  21. Kitchens WH. Domino liver transplantation: Indications, techniques, and outcomes. Transplantation Reviews. 2011;25:167.
  22. Yu Y, et al. Cell therapies for liver diseases. Liver Transplantation. 2012;18:9.
  23. Croome KP, et al. The use of donation after cardiac death allografts does not increase recurrence of hepatocellular carcinoma. American Journal of Transplantation. 2015;15:2704.
  24. De Assuncao TM, et al. Development and characterization of human-induced pluripotent stem cell-derived cholangiocytes. Laboratory Investigation. 2015;95:684.
  25. Riggin EA. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Feb. 15, 2016.
  26. Brown AY. Allscripts EPSi. Mayo Clinic, Rochester, Minn. March 22, 2016.
  27. Cook AJ. Allscripts EPSi. Mayo Clinic, Rochester, Minn. May 2, 2014.
  28. Krowka MJ, et al. International Liver Transplant Society practice guidelines: Diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension. Transplantation. 2016;100:1440.
  29. Patel K, et al. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus. World Journal of Gastroenterology. 2011;17:4581.
  30. Singh S, et al. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: A diagnostic accuracy systematic review and individual participant data pooled analysis. European Radiology. 2016;26:1431.
  31. Han L, et al. Extracorporeal liver support and liver transplant for patients with acute-on-chronic liver failure. Seminars in Liver Disease. 2016;36:153. https://www.thieme-connect.de/products/ejournals/html/10.1055/s-0036-1583197. Accessed June 29, 2016.
  32. Gallagher C. Transplant genomics enters collaboration with Mayo Clinic (news release). Mayo Clinic, Rochester, Minn. June 27, 2016.
  33. Heilman RL (expert opinion). Mayo Clinic, Phoenix/Scottsdale, Ariz. June 24, 2016.

Mayo Clinic in Minnesota has been recognized as the best Gastroenterology & GI Surgery hospital in the nation for 2017-2018 by U.S. News & World Report.

Learn more about this top honor

Liver Transplant Program

Research: It's All About Patients

Sections